Cytokinetics(US:CYTK) Globenewswire·2025-09-28 12:29Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Inc. for allegedly making false and misleading statements regarding the New Drug Application (NDA) for aficamten, which may have caused investor losses during the specified Class Period from December 27, 2023, to May 6, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Cytokinetics misrepresented the expected timeline for FDA approval of aficamten, indicating it would occur in the second half of 2025, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS) [5]. - Investors who purchased Cytokinetics common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - The Rosen Law Firm, which has a strong track record in securities class actions, is representing the investors and encourages them to select qualified counsel with proven success [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been recognized for its leadership in securities class action settlements [4]. Group 3: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the firm directly for more information [3][6]. - A lead plaintiff must be appointed by November 17, 2025, to represent the interests of the class members in the litigation [1][3].